Indivior

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Indivior
Public company
Traded asLSEINDV
Industrypharmaceuticals
Founded1994
HeadquartersRichmond, Virginia
Key people
Howard Pien, Chairman
Shaun Thaxter, CEO
ProductsSubutex/Subuxone
Revenue$1,005 million (2018)[1]
$292 million (2018)[1]
$275 million (2018)[1]
OwnerNorthern Cross (6.75%), Janus Capital Group (5.68%), M&G Investments (5.16%), Fidelity Investments (5.06%) Edit this on Wikidata
Number of employees
915 (2018)[1]
Websitewww.indivior.com/

Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange.

History[edit]

The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]

In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with justice department to pay $1.4 billion to resolve U.S. federal investigation into sales and marketing of opioid addiction treatment.[5][6][7]

Operations[edit]

The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[8]

References[edit]

  1. ^ a b c d "Annual Report 2018" (PDF). Indivior. Retrieved 18 March 2019.
  2. ^ a b "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. ^ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. ^ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
  5. ^ Reuters (11 July 2019). "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. ISSN 0362-4331. Retrieved 11 July 2019.
  6. ^ admin. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Retrieved 11 July 2019.
  7. ^ "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. 11 July 2019. Retrieved 11 July 2019.
  8. ^ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.

External links[edit]